Partnerships in molecular diagnostics.
Cervixel partners with biotech, pharma, and clinical research groups on molecular diagnostics. Engagements are scoped tightly and run on written milestones.
Five lines of work.
Each engagement is scoped on its own. Most clients begin with one and grow into another as the programme moves.
- Service
CRISPR assay development
Design and optimisation of Cas-based detection assays for nucleic-acid targets in clinical and research settings.
- Service
Molecular diagnostics consulting
Strategic guidance on assay architecture, sample workflows, and translation from concept to clinical use.
- Service
Clinical validation support
Study design, partner sourcing, and analytical-to-clinical performance evaluation for diagnostic candidates.
- Service
Regulatory strategy
IVDR-aligned planning for CE marking pathways, technical-file structuring, and post-market surveillance.
- Service
Contract research
Targeted laboratory work for biotech and pharmaceutical partners — flexible scope, rigorous documentation.
- Service
Global procurement services
Sourcing of medical devices, IVDs, and pharmaceuticals from European supply chains for international partners, with full audit and compliance documentation.
How partnerships work.
Three steps, no surprises. Anything that isn't in the written scope isn't in the work.
- Step 01
Discovery call
We start with a short conversation to understand the question, the constraints, and what success looks like. No proposal yet — just enough to know whether we're a useful partner.
- Step 02
Scoped proposal
If the engagement makes sense, we send a written scope: what we'll do, what you'll get, on what timeline, at what fee. Nothing in the work changes without a written change to the scope.
- Step 03
Delivery
Work runs in milestones with documented outputs at each step. You see the artifacts as they land — protocols, plans, reports — not all at once at the end.
Bring us your hardest question.
Whether you’re scoping a programme, evaluating a pivot, or running diligence, we’d like to hear from you.